Clinical Trial Update: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis [Phase 3]

View source ↗

Summary

This document describes a Phase 3 pediatric clinical trial evaluating the efficacy and safety of ofatumumab and siponimod compared with fingolimod in children w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)
• Kesimpta (ofatumumab)
• MAYZENT (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis (MS) | Phase 3 | Status: ACTIVE_NOT_RECRUITING